Results 41 to 50 of about 282,663 (297)
A case of CALR mutation in JAK2-negative patient with polycythemia
Онкогематология, 2022 JAK2 mutations can be associated with any phenotypic form of chronic myeloproliferative neoplasia, while MPL and CALR mutations occur, as a rule, in cases of essential thrombocythemia and primary myelofibrosis and they are not observed in polycythemia ...
T. N. Subbotina +8 more
doaj +1 more source
Macrophages support pathological erythropoiesis in Polycythemia Vera and Beta-Thalassemia [PDF]
, 2014 Regulation of erythropoiesis is achieved by integration of distinct signals. Among these, macrophages are emerging as erythropoietin-complementary regulators of erythroid development, particularly under stress conditions. We investigated the contribution
Abdel-Wahab, Omar +15 more
core +1 more source
Blood, 2020 There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera (PV), as much of the published literature on the topic does not appropriately utilize repeated ...
L. Ronner +32 more
semanticscholar +1 more source
Double Thrombosis- Interesting Case of Polycythemia Vera [PDF]
Journal of Clinical and Diagnostic Research, 2020 Polycythemia vera is a myeloproliferative disorder which has a varied manifestation, one of it being venous thrombosis and arterial thrombosis which significantly contributes to the mortality and morbidity.
Subashini Subramanian +1 more
doaj +1 more source
Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]
, 2019 Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela +1 more
core +1 more source
Blood Advances, 2020 Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is ...
A. Masciulli +4 more
semanticscholar +1 more source
Hereditary hemochromatosis and JAK2‐positive polycythemia vera
Clinical Case Reports, 2021 A 59‐year‐old man was diagnosed with JAK2‐positive polycythemia vera. Subsequently, further laboratory testing revealed elevated ferritin and iron saturation.
Ahmed Radwan, Ibraheem Othman
doaj +1 more source
New Perspectives on Polycythemia Vera: From Diagnosis to Therapy
International Journal of Molecular Sciences, 2020 Polycythemia vera (PV) is mainly characterized by elevated blood cell counts, thrombotic as well as hemorrhagic predisposition, a variety of symptoms, and cumulative risks of fibrotic progression and/or leukemic evolution over time.
A. Iurlo +3 more
semanticscholar +1 more source
Feline primary erythrocytosis: a multicentre case series of 18 cats [PDF]
, 2018 A retrospective multicentre case series of feline primary erythrocytosis (PE) was evaluated. The aim was to gain better understanding of disease presentation and progression to guide management and prognostication. Case records were assessed for evidence
Balazs Szladovits +7 more
core +1 more source
Givinostat: an emerging treatment for polycythemia vera
Expert Opinion on Investigational Drugs, 2020 Introduction Polycythemia vera (PV), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 mutation.
H. Chifotides, P. Bose, S. Verstovsek
semanticscholar +1 more source